Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 6/20 | 0.47 |
| ▸ | PDE1B | Q01064 | 6/20 | 0.47 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.47 |
| ▸ | PDE2A | O00408 | 3/20 | 0.47 |
| ▸ | PDE5A | O76074 | 3/20 | 0.40 |
| ▸ | CFTR | P13569 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | PDE6C | P51160 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4762458 | 0.89 | PDE1A (0.44) | PDE1APDE1BPDE1CPDE2APDE5A | |
| SCHEMBL4770944 | 0.89 | ADORA2A (0.39) | PDE1APDE1BPDE1CPDE2ACFTR | |
| SCHEMBL17941788 | 0.83 | PDE1A (0.43) | PDE1APDE1BPDE1CPDE2APDE5A | |
| SCHEMBL4763645 | 0.83 | SIRT1 (0.40) | PDE1APDE1BPDE1CPDE2ACYP1A2 | |
| SCHEMBL4767903 | 0.81 | RGS4 (0.46) | PDE1APDE1BPDE1CPDE2ACYP1A2 | |
| SCHEMBL4058469 | 0.81 | KDM4E (0.42) | PDE4AMAPK1PDE4BPDE4CPDE4D | |
| SCHEMBL4762679 | 0.81 | PDE5A (0.33) | PDE1APDE1BPDE1CPDE2APDE5A | |
| SCHEMBL4766301 | 0.80 | RGS4 (0.47) | PDE1APDE1BPDE1CPDE2ACYP1A2 | |
| SCHEMBL8174835 | 0.78 | NCOA1 (0.43) | CYP1A2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30799164 | 0.77 | ADORA2B (0.43) | MAPK1KDM4EALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | PDE1A 912/4885PDE1B 545/4885PDE1C 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.